Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436410 · ClinicalTrials.gov registry record · Early Phase 1
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
A Early Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 108
- Enrollment target
NCT00436410 is a Early Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 108 participants.
The verdict
NCT00436410, a Early Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing. Studying tumor necrosis factor in samples of tumor tissue and healthy tissue from patients with cancer in the laboratory may help doctors learn how tumor necrosis factor works in tumor tissue and healthy tissue. PURPOSE: This clinical trial is studying tumor necrosis factor in patients undergoing surgery for primary cancer or metastatic cancer .
Interventions
- OTHER pharmacological study
- PROCEDURE conventional surgery
- OTHER electron microscopy
- BIOLOGICAL colloidal gold-bound tumor necrosis factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436410
The ClinicalTrials.gov registry entry for NCT00436410 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pharmacological study is the first listed.
NCT00436410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00436410 about?
NCT00436410 is a clinical study titled "Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer". RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing. Studying tumor necrosis factor in samples of tumor tissue and healthy tissue from patients with cancer in the laboratory may help doctors learn how tum...
What is the current status of trial NCT00436410?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 108 participants. The study started on 2006-12. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00436410?
The interventions under investigation include: pharmacological study (OTHER), conventional surgery (PROCEDURE), electron microscopy (OTHER), colloidal gold-bound tumor necrosis factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00436410?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.